-+ 0.00%
-+ 0.00%
-+ 0.00%

Huhuang Pharmaceutical announced that following the completion of the medical insurance contract renewal with the National Health Insurance Administration, Elliot, Warisa, and Suteida will continue to be included in the new national medical insurance drug catalogue effective from January 1, 2027. This update covers the inclusion of new indications, renewal of existing indications, and ongoing coverage under the current multi-year agreement. Among them, Elute was included in combination with cindilizumab injections to treat patients with locally advanced or metastatic renal cell carcinoma who have not received PD-1 or PD-L1 inhibitors before receiving VEGFR-TKI treatment; Vorisha was included in combination with osimitinib to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with MET amplification that progressed after EGFR-TKI treatment with EGFR-TKI treatment, and their MET exon 14 transition indications were also renewed.

智通财经·11/16/2026 04:17:03
语音播报
Huhuang Pharmaceutical announced that following the completion of the medical insurance contract renewal with the National Health Insurance Administration, Elliot, Warisa, and Suteida will continue to be included in the new national medical insurance drug catalogue effective from January 1, 2027. This update covers the inclusion of new indications, renewal of existing indications, and ongoing coverage under the current multi-year agreement. Among them, Elute was included in combination with cindilizumab injections to treat patients with locally advanced or metastatic renal cell carcinoma who have not received PD-1 or PD-L1 inhibitors before receiving VEGFR-TKI treatment; Vorisha was included in combination with osimitinib to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with MET amplification that progressed after EGFR-TKI treatment with EGFR-TKI treatment, and their MET exon 14 transition indications were also renewed.